<DOC>
	<DOCNO>NCT02781558</DOCNO>
	<brief_summary>This study evaluate efficacy , safety , tolerability sofosbuvir /velpatasvir ( SOF/VEL ) fix dose combination ( FDC ) SOF/VEL FDC Ribavirin ( RBV ) 12 week participant chronic genotype 3 HCV infection compensate cirrhosis .</brief_summary>
	<brief_title>Efficacy Safety Sofosbuvir/Velpatasvir Fixed Dose Combination ( FDC ) Sofosbuvir/Velpatasvir FDC Ribavirin Participants With Chronic Genotype 3 HCV Infection Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Male nonpregnant/ nonlactating female individual Individuals chronic genotype 3 HCV infection compensate cirrhosis Laboratory value within threshold screening Individuals without HIV1 coinfection Key History clinically significant illness medical disorder may interfere individual 's treatment assessment compliance protocol Coinfection acute hepatitis B virus Known hypersensitivity study medication Use prohibit concomitant medication within window Day 1 visit . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>